BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Cell Therapy
    • COVID-19
    • CAR-T
    • Cord Blood
  • Exosomes
  • Interviews
  • News
    • Press Releases
    • Job Posts
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » Coronavirus » Page 3

FDA Approves Phase II Trial of Hope Biosciences’ MSCs Against COVID-19

April 9, 2020 By Cade Hildreth (CEO)

Autologous Mesenchymal Stem Cells to Provide Immune Support Against COVID-19

HOUSTON, April 6, 2020 — Hope Biosciences, a clinical stage biotechnology company focused on developing cell-based therapeutics for acute and chronic disease, today announced that FDA has approved a Phase II clinical trial evaluating efficacy and safety of Hope Biosciences’ autologous, adipose-derived mesenchymal stem cells (HB-adMSCs) to provide immune support against COVID-19.

MSCs are well-known for their immunomodulatory and regenerative potential. In a recent Phase I/II clinical trial for Rheumatoid Arthritis, results appeared to show that HB-adMSCs were safe and effective in attenuating systemic inflammation. In COVID-19 patients, inflammation is a driving force behind disease progression, and it is critical to regulate the immune system as early as possible. [Read more…]

Filed Under: Coronavirus (COVID-19) Tagged With: Coronavirus

COVID-19 Vaccine: IntelliStem Technologies Announces Successful Development of Peptide-Based Vaccine Against COVID-19

April 6, 2020 By Cade Hildreth (CEO)

Intellistem

TORONTO, ON – April 6th, 2020—INTELLiSTEM Technologies Inc, a biotechnology company pioneering cellular vaccines and peptide therapeutics, announced the successful development of a peptide-based vaccine (IPT-001) intended for human use against COVID-19.

IPT-001 is a peptide-based vaccine developed using the novel coronavirus COVID-19. It was engineered using INTELLiPEPTIDOME™ Platform to target both the Spike (S) and Nucleocapsid (N) proteins. [Read more…]

Filed Under: Coronavirus (COVID-19) Tagged With: Coronavirus

Citius to License Novellus’ iPSC-derived MSCs for COVID-19 Related Complications

April 4, 2020 By Cade Hildreth (CEO)

Citius Novellus iPSC-derived MSCs

– Novellus’ patented mRNA-based cell-reprogramming technology creates MSCs with superior immunomodulatory properties

– Novellus’ iPSC-derived MSCs have manufacturing advantages over primary adult, donor-derived MSCs, allowing for larger supply, faster scale-up, and a more consistent cellular product

– MSCs may remedy the cytokine storm that triggers acute respiratory distress syndrome (ARDS) in COVID-19 patients

[Read more…]

Filed Under: Coronavirus (COVID-19), MSCs Tagged With: Coronavirus

Aspire Announces Filing of a Pre-IND Meeting Request with U.S. FDA and a Pre-CTA Meeting Request with Health Canada for its ACT-20 Cellular Therapy against COVID-19 Pneumonia

April 3, 2020 By Cade Hildreth (CEO)

Aspire Health Science

ORLANDO, Florida, March 31st, 2020 – Aspire Health Science, LLC (the “Company” or “Aspire”), an FDA registered manufacturing facility specialized in the development and manufacturing of cell-based therapies, is pleased to announce that it has filed its pre-IND (Investigational New Drug) meeting request with the U.S. FDA and Pre-CTA (Clinical Trial Application) with Health Canada. A complete briefing package accompanied the meeting requests. This initiates formal communications between Aspire and both the U.S. FDA and Health Canada regarding development of the Company’s cellular therapy, ACT-20 for the treatment of severe COVID-19 Pneumonia. [Read more…]

Filed Under: Coronavirus (COVID-19) Tagged With: Coronavirus

COVID-19 News: Role of Cell Therapies in COVID-19 Complications

April 2, 2020 By Cade Hildreth (CEO)

Coronavirus COVID-19 market

Coronavirus disease (COVID-19) is a global pandemic that is threatening the viability of healthcare systems worldwide. The virus responsible for the disease is also known as severe acute respiratory syndrome coronavirus 2 and abbreviated as SARS-CoV-2. The eruption started in China on December 29, 2019, and by March 2020, it had spread to at least 180 countries and territories worldwide. [Read more…]

Filed Under: Coronavirus (COVID-19) Tagged With: Coronavirus

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next Page »

Let’s Get Social

  • Facebook
  • Twitter
  • Instagram
  • Pinterest
  • LinkedIn

Nanocellect

Marathon Products

Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Top Rated Products

  • US Cord Blood and Cord Tissue Storage Rates Rates of U.S. Cord Blood and Cord Tissue Storage - Historical and Projected
    Rated 0 out of 5
    $197
  • Job Posting on BioInformant Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience
    Rated 0 out of 5
    $297
  • BioInformant Audience Reach BioInformant's Audience with Your Press Announcement
    Rated 0 out of 5
    $397 $297
My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2021 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: [email protected] | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.